Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Research
Molecular Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Cancer Genes and Genomics

Inhibition of Hypoxia-Inducible Factor Is Sufficient for Growth Suppression of VHL−/− Tumors1 1 NIH grant R29CA78358-06 (O. I.), Bertucci Fund for Urologic Malignancies (O. I.), David P. Foss Fund (O. I.), and VHL Family Alliance 2003 award (M. Z.).

Michael Zimmer, Darrell Doucette, Naila Siddiqui and Othon Iliopoulos
Michael Zimmer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Darrell Doucette
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naila Siddiqui
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Othon Iliopoulos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published February 2004
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Inhibition of HIF2α in VHL−/− cells by shRNAi. VHL−/− 786-O cells were stably transfected with pSR or pTU6 plasmids expressing shRNA targeting HIF2α or control empty vector. A. Normalized HRE-driven luciferase activity in shRNAi versus control clones. B. Western blot analysis for HIF2α expression in HIF2α shRNAi and pVHL-reconstituted clones versus vector-only control clones. Bar graph quantitates relative HIF2α levels normalized for actin loading control.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    shRNAi of HIF2α decreases expression of HIF target genes. A. ELISA for secreted VEGF concentration in tissue culture supernatants of HIF2α shRNAi and pVHL-reconstituted clones versus vector-only control clones. Bars, SEM. Differences in VEGF expression between pVHL-reconstituted or HIF2α knockdown clones and their respective control clones were significant (P < 0.01). B. Western blot analysis for Glut-1 expression in the HIF2α shRNAi clones was performed using unboiled samples with one-tenth of the lysate volume loaded in Fig. 1. Bar graph quantitates relative Glut-1 expression normalized for actin loading control (shown in Fig. 1).

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    HIF2α inhibition prevents response to hypoxia. A. ELISA for secreted VEGF concentration in tissue culture supernatants of HIF2α shRNAi and pVHL-reconstituted clones versus respective vector-only control clones under normoxic (21% O2, gray bars) and hypoxic (1% O2, white bars) conditions. Bars, SEM. Differences in VEGF expression between pVHL-reconstituted (WT8) or HIF2α knockdown clones (pSR1, pTR1, pTR2, and pTR3) and their respective control clones (pRC3, pSV1, and pTV1) were significant (P < 0.01), whereas differences in the hypoxic induction of VEGF were significant for the pVHL-reconstituted WT8 cells only (P < 0.05). B. Western blot analysis for HIF2α expression in cells under normoxic and hypoxic conditions (denoted as N and H, respectively). Bar graph quantitates relative HIF2α levels normalized for actin loading control. A and B. Gray bars, normoxia; white bars, hypoxia.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    In vitro cell proliferation is not affected by HIF2α-directed shRNAi. Cell proliferation measured via cleavage of the tetrazolium salt WST-1 at the indicated time points. Bars, SEM. Closed squares, PRC3; open squares, WT8; closed triangles, pTV1; open triangles, pTR1. Similar results were obtained for pSV1, pSR1, pTV2, pTR2, and pTR3 cells (data omitted for the sake of clarity).

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    HIF2α-directed shRNAi reduces the overall proangiogenic activity of conditioned supernatant. HUVEC proliferation as measured by WST-1 cleavage in the presence of conditioned supernatant from PRC3, WT8, pSV1, pSR1, pTV1, and pTR1 clones. Differences between shRNAi and pVHL-reconstituted clones versus vector-only control clones were significant. Bars, SEM.

  • FIGURE 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 6.

    HIF2α-directed shRNAi suppresses tumor formation. A. Average tumor mass resulting from cells injected into the flank of nude mice. n, number of injection sites for each clone. All differences in tumor mass relative to the corresponding vector-only control cell injections were statistically significant (P < 0.01). Bars, SEM. B. Representative mice injected with cells in which pVHL function was reconstituted (WT8) versus HIF activity was inhibited (pSR1) along with corresponding control injections.

Tables

  • Figures
  • Table 1.

    Description of Cell Lines Used in This Study

    CloneDescriptionReference
    786-OEstablished VHL−/− RCC cell line(39)
    PRC3786-O-derived clone stably transfected with empty pcDNA3 vector(11)
    WT8786-O-derived clone stably transfected with pcDNA3::HA-VHL30(11)
    pSV1786-O-derived clone stably transfected with empty pSR vectorThis work
    pSR1786-O-derived clone stably transfected with pSR targeting HIF2αThis work
    pTV1786-O-derived clone stably transfected with empty pTU6IIa vectorThis work
    pTV2786-O-derived clone stably transfected with empty pTU6IIa vectorThis work
    pTR1786-O-derived clone stably transfected with pTU6IIa targeting HIF2αThis work
    pTR2786-O-derived clone stably transfected with pTU6IIa targeting HIF2αThis work
    pTR3786-O-derived clone stably transfected with pTU6IIa targeting HIF2αThis work
PreviousNext
Back to top
Molecular Cancer Research: 2 (2)
February 2004
Volume 2, Issue 2
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inhibition of Hypoxia-Inducible Factor Is Sufficient for Growth Suppression of VHL−/− Tumors1 1 NIH grant R29CA78358-06 (O. I.), Bertucci Fund for Urologic Malignancies (O. I.), David P. Foss Fund (O. I.), and VHL Family Alliance 2003 award (M. Z.).
(Your Name) has forwarded a page to you from Molecular Cancer Research
(Your Name) thought you would be interested in this article in Molecular Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Inhibition of Hypoxia-Inducible Factor Is Sufficient for Growth Suppression of VHL−/− Tumors1 1 NIH grant R29CA78358-06 (O. I.), Bertucci Fund for Urologic Malignancies (O. I.), David P. Foss Fund (O. I.), and VHL Family Alliance 2003 award (M. Z.).
Michael Zimmer, Darrell Doucette, Naila Siddiqui and Othon Iliopoulos
Mol Cancer Res February 1 2004 (2) (2) 89-95;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Inhibition of Hypoxia-Inducible Factor Is Sufficient for Growth Suppression of VHL−/− Tumors1 1 NIH grant R29CA78358-06 (O. I.), Bertucci Fund for Urologic Malignancies (O. I.), David P. Foss Fund (O. I.), and VHL Family Alliance 2003 award (M. Z.).
Michael Zimmer, Darrell Doucette, Naila Siddiqui and Othon Iliopoulos
Mol Cancer Res February 1 2004 (2) (2) 89-95;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Results
    • Discussion
    • Materials and Methods
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • GRM1 Suppression in Human Melanoma Cells
  • SINE Retrotransposons Cause Epigenetic Reprogramming
  • Genomic Targets and Role in Cell Survival of AEBP1
Show more Cancer Genes and Genomics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Rapid Impact Archive
  • Meeting Abstracts

Information for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCR

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Research
eISSN: 1557-3125
ISSN: 1541-7786

Advertisement